Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**PNID** is a highly non-specific acronym that refers to several distinct entities in medical and scientific literature, including two drug candidates, multiple disease categories, and a psychological assessment tool. As a drug, **PNID** primarily refers to: 1) **chi-conotoxin PnID** (or **PnID**), a novel peptide isolated from the venom of the marine snail *Conus pennaceus* that acts as a selective inhibitor of the **norepinephrine transporter (NET)**, currently being researched for the treatment of **neuropathic pain** and other neurological disorders; and 2) **Paning I decoction (PNID)**, a traditional Chinese herbal formula investigated for its neuroprotective effects in **Parkinson's disease**. The decoction's mechanism involves reducing neuroinflammation by inhibiting fibrinogen deposition, modulating microglial polarization from the pro-inflammatory M1 state to the anti-inflammatory M2 state, and repairing the blood-brain barrier. Beyond these drugs, PNID is a common abbreviation for **Pediatric Neuroimmunological Disorders**, **Pulmonary Non-Infectious Disease**, and the **Peer Nomination Inventory of Depression** (a scale used to evaluate childhood depression).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PNID.